Literature DB >> 6418214

Decreased ganglioside neuraminidase activity in fibroblasts from mucopolysaccharidosis patients. Inhibition of the activity in vitro by sulfated glycosaminoglycans and other compounds.

J Baumkötter, M Cantz.   

Abstract

The neuraminidase activities towards the ganglioside substrates GD1a, GD3 and GM3 were found to be markedly diminished in homogenates of fibroblasts cultured from patients with various genetic mucopolysaccharidoses. Mixing normal and patients' fibroblast homogenates revealed this effect to be due to the presence of diffusible inhibitors. The neuraminidase acting on the trisaccharide sialyllactose, on the other hand, showed normal activity in all the cell lines tested. Experiments in vitro revealed the sulfated glycosaminoglycans chondroitin 4-sulfate and heparin, the polysaccharide dextran sulfate, and the trypanocidal drug suramin to be strongly inhibitory on the ganglioside GD1a neuraminidase activity of normal fibroblast homogenates. Regarding chondroitin 4-sulfate, this inhibition was of the non-competitive type. A disulfated tetrasaccharide prepared from chondroitin 4-sulfate, on the other hand, was not at all inhibitory. These and additional findings led us to propose a model for the interaction between enzyme and inhibitor, involving a 'clamping' mechanism by the polysulfated compounds. We conclude that the decreased ganglioside neuraminidase activities of mucopolysaccharidosis fibroblasts are due to an inhibition by the accumulated sulfated glycosaminoglycans and that such inhibition is responsible for the storage of certain gangliosides in the tissues of the patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6418214     DOI: 10.1016/0304-4165(83)90225-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

Review 1.  Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.

Authors:  Dao Pan
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

2.  Secondary storage of dermatan sulfate in Sanfilippo disease.

Authors:  William C Lamanna; Roger Lawrence; Stéphane Sarrazin; Jeffrey D Esko
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

Review 3.  Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms.

Authors:  Derbis Campos; Madelyn Monaga
Journal:  Metab Brain Dis       Date:  2012-04-14       Impact factor: 3.584

4.  Specificity studies on the oligosaccharide neuraminidase of human fibroblasts.

Authors:  K Mendla; M Cantz
Journal:  Biochem J       Date:  1984-03-01       Impact factor: 3.857

5.  N-Acetylneuraminic acid storage disease.

Authors:  J Baumkötter; M Cantz; K Mendla; W Baumann; H Friebolin; J Gehler; J Spranger
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

6.  Caprine mucopolysaccharidosis IIID: fetal and neonatal brain and liver glycosaminoglycan and morphological perturbations.

Authors:  Margaret Z Jones; Joseph Alroy; Erinn Downs-Kelly; Rebecca E Lucas; Stacey A Kraemer; Kevin T Cavanagh; Barbara King; John J Hopwood
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

7.  Ganglioside GM3 sialidase activity in fibroblasts of normal individuals and of patients with sialidosis and mucolipidosis IV. Subcellular distribution and and some properties.

Authors:  M Lieser; E Harms; H Kern; G Bach; M Cantz
Journal:  Biochem J       Date:  1989-05-15       Impact factor: 3.857

8.  Alterations in neuron morphology in mucopolysaccharidosis type I. A Golgi study.

Authors:  S U Walkley; M E Haskins; R M Shull
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

Review 9.  Secondary lipid accumulation in lysosomal disease.

Authors:  Steven U Walkley; Marie T Vanier
Journal:  Biochim Biophys Acta       Date:  2008-12-09

Review 10.  Neurobiology and cellular pathogenesis of glycolipid storage diseases.

Authors:  Steven U Walkley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-05-29       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.